Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company focused on advanced therapies for the sports medicine and severe burn care markets. Its news flow centers on financial performance, adoption of its cell therapy and biologic products, and progress in clinical and manufacturing initiatives.
Investors following VCEL news can expect regular quarterly earnings releases detailing total revenue, product-level revenue for MACI and Burn Care (Epicel and NexoBrid), gross margin, net income or loss, adjusted EBITDA and operating cash flow. Vericel frequently provides financial guidance ranges for full-year revenue, MACI growth, gross margin and adjusted EBITDA margin, and may update these expectations as the year progresses.
Company updates also highlight operational metrics such as record MACI revenue, numbers of MACI implants and biopsies, growth in trained MACI Arthro surgeons, Epicel and NexoBrid biopsy and hospital order trends, and expansion of the MACI sales force. These disclosures offer insight into market penetration and utilization of Vericel’s therapies in orthopedic and burn care settings.
Vericel news items often include information on clinical and regulatory milestones, such as FDA IND clearance for the Phase 3 MACI Ankle clinical study and the initiation of the MACI Ankle MASCOT clinical trial. The company also announces participation in major investor and healthcare conferences, including events hosted by J.P. Morgan, Stephens, Wells Fargo and Truist Securities, where management discusses business performance and strategy.
This VCEL news page aggregates these press releases and related announcements so readers can review historical and recent developments around Vericel’s financial results, product adoption, clinical programs and corporate presentations in one place.
Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2022 financial results on November 9, 2022. The company specializes in advanced therapies for sports medicine and severe burn care, marketing two prominent cell therapy products: MACI and Epicel. A conference call will be held at 8:30 a.m. ET to discuss the results and key business highlights. Interested parties can join via a live webcast on the company's Investor Relations website. Presentation slides will also be available during the call.
Vericel Corporation (NASDAQ:VCEL) announced that Chief Financial Officer Joe Mara will present at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:30 p.m. ET. This event highlights the company’s commitment to sharing insights about its advanced therapies in sports medicine and burn care. A webcast of the presentation will be accessible via the Investor Relations section of Vericel's website, ensuring that stakeholders can stay informed about the company’s developments.
Vericel Corporation (NASDAQ:VCEL) announced its participation in two upcoming investor conferences. On September 13, 2022, at 8:00 a.m. ET, President and CEO Nick Colangelo and CFO Joe Mara will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference. The following day, September 14, 2022, Joe Mara will present at the H.C. Wainwright 24th Annual Global Investment Conference at 9:00 a.m. ET. Webcasts of both events will be accessible via the Investor Relations section of Vericel's website.
Vericel Corporation (NASDAQ:VCEL) reported second-quarter 2022 net revenue of $37.0 million, a decline from $39.5 million in Q2 2021. MACI® revenue increased to $28.6 million, growing 8% year-over-year. The company posted a net loss of $9.0 million ($0.19 per share) and a 62% gross margin. Operating expenses rose to $31.9 million. Cash resources remain robust at $131 million with no debt. Guidance for total revenue is maintained at $178-$189 million for 2022, with a projected gross margin of 69%.
Data published in the Journal of Burn Care & Research highlights a retrospective study on 40 patients with significant posterior burns treated with Epicel by the Burn and Reconstructive Centers of America. Key findings include an 83% engraftment success rate after one or two applications and a 90% survival rate. The study underscores the effectiveness of standardized treatment protocols for enhancing patient outcomes in severe burns. Epicel is approved for deep dermal or full-thickness burns covering at least 30% of total body surface area.
Vericel Corporation (NASDAQ:VCEL) will announce its second-quarter 2022 financial results on August 3, 2022, at 8:30 a.m. ET. The company specializes in advanced therapies for sports medicine and severe burn care, marketing MACI® and Epicel®, two cell therapy products. A conference call and webcast will follow the results announcement, accessible through their Investor Relations website. Vericel also holds the exclusive North American license for NexoBrid®, a product for severe thermal burns.
Vericel Corporation (NASDAQ:VCEL) reported a 4% increase in total net revenue to $36.1 million for Q1 2022, compared to $34.6 million in Q1 2021. MACI revenue was $26.0 million, while Epicel generated $9.9 million. The company's gross margin stood at 65%, down from 66% a year earlier. However, it experienced a net loss of $7.1 million or $0.15 per share, compared to $3.3 million in Q1 2021. Adjusted EBITDA decreased to $3.2 million. The company maintains its full-year guidance of $178 to $189 million in total revenue.
Vericel Corporation (NASDAQ:VCEL) will host a webcast and conference call on May 4, 2022, at 8:30 AM ET to discuss its Q1 2022 financial results and business highlights. The call will be accessible via the Investor Relations section of the company’s website. Vericel specializes in advanced therapies for sports medicine and severe burn care, offering cell therapy products such as MACI and Epicel, and has an exclusive license for NexoBrid in North America.
Vericel Corporation (NASDAQ:VCEL), known for its advanced therapies in sports medicine and severe burn care, announced that President and CEO Nick Colangelo will present at the Canaccord Genuity Musculoskeletal Conference in Chicago on March 22, 2022, at 11:00 a.m. Central Time. A webcast of the presentation will be accessible via the Investor Relations section of Vericel's website.
Vericel markets two primary cell therapy products: MACI®, for knee cartilage repair, and Epicel®, a skin replacement for severe burns. Additionally, the company holds rights to NexoBrid®, a product for burn debridement.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will speak at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. ET. The event will be accessible via a webcast on the company's Investor Relations website.
Vericel focuses on advanced therapies for sports medicine and severe burn care, marketing MACI® for knee cartilage repair and Epicel® for severe burns treatment. The company also has rights to NexoBrid® for burn debridement, enhancing its product portfolio.